Baird lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $320 from $325 and keeps an Underperform rating on the shares. The firm noted the approval of Journavax which was widely expected.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $435 from $418 at Barclays
- Vertex Pharmaceuticals announces Casgevy reimbursement pact with NHS England
- Vertex (VRTX) Secures FDA Approval for Highly-Awaited Non-Opioid Painkiller
- Closing Bell Movers: Atlassian up 19%, Apple gains 3% after results
- Vertex Pharmaceuticals announces FDA approval of Journavx